An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Uncertain about how you can stay healthy on a tight budget, especially when bombarded with misinformation from social media ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...
CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
I was living a normal 29-year-old life. I thought my symptoms were no big deal, until they started happening more ...
The IRA bombings in Hyde Park and Regent’s Park on July 20, 1982 became a life-defining moment for Gareth Collett.
The Vancouver Sun on MSN
This made-in-B.C. preventive surgery lowers ovarian cancer risk
Opportunistic salpingectomy, or the removal of fallopian tubes in women already undergoing another abdominal or gynecological ...
Urothelial tumours represent the 6th most frequent cancer in men and its incidence continues to rise in both sexes. Fortunately, approximately 75% of ...
The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...
Morning Overview on MSN
Why cancer returns years later, and how we can stop it
Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...
Sooty helmets were once a badge of honor. But research shows firefighters absorb carcinogenic particles through their skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback